The major mechanisms of endocrine resistance in ER+ breast cancers, through ERα itself, receptor tyrosine kinase (RTK) signaling, or cell cycle regulation with the cyclin D-CDK4/6-Rb pathway, have been demonstrated to be pivotal in endocrine therapy2. Here, RB1 is linked to breast cancer.